MedTrace Logo

Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Chronic Heart Failure

NCT00843154 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 571

Last updated 2010-06-11

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of Candesartan, once daily (QD), added to ongoing chronic heart disease therapy in measuring brain natriuretic peptide in patients with chronic heart failure.

Conditions

Interventions

DRUG

Candesartan and standard chronic heart disease therapy

Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.

DRUG

Standard chronic heart disease therapy

Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.

Sponsors & Collaborators

Principal Investigators

  • Medical Director Director · Takeda Italia Farmaceutici SpA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2008-07-31
Completion
2008-07-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00843154 on ClinicalTrials.gov